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Abstract  In  haematological  malignancies,  the  development  of  lung  disease  is  a  common
source of  signiﬁcant  morbidity  and  mortality  for  this  population  of  patients.  There  is  a
wide range  of  infectious  and  non-infectious  aetiologies  that  can  be  responsible  for  such
complications.  It  is  a  major  challenge  to  make  an  early  diagnosis  of  aetiology  in  order  to  choose
the most  suitable  treatment.  Computed  tomography  (CT)  of  the  chest  has  undeniably  become
a crucial  tool  in  diagnosing  these  cases  of  lung  disease.  Although  it  is  not  possible  to  make  a
deﬁnitive diagnosis  of  aetiology  based  solely  on  analysing  CT  scan  ﬁndings  in  these  complex
patients, there  are  some  abnormalities  that  are  highly  suspicious  for  particular  diagnoses.  CT,
therefore,  allows  the  clinician  to  put  forward  and  prioritise  possible  diagnoses  that  may  then
be considered  in  view  of  clinical  information  and  laboratory  study  results.  There  must  be  mul-
tidisciplinary  involvement  in  the  management  of  lung  disease  patients  and  there  must  be  an
ongoing dialogue  between  the  radiologist  and  the  clinician.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Abbreviations
CT  Computed  tomography
HSC  Haematopoietic  stem  cells
CMV  CytomegalovirusIntroduction
It  is  common  for  lung  disease  to  develop  in  patients  who  are  being  managed  for  malig-
nant  haematological  disease.  Indeed,  over  half  of  these  patients  present  pulmonary
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cLung  disease  and  haematological  malignancies  
abnormalities  during  their  follow-up,  and  these  could
relate  to  any  of  a  large  number  of  both  infectious  and
non-infectious  diseases,  with  a  signiﬁcant  burden  of  mor-
bidity  and  mortality  [1].  Management  of  these  kinds  of
complications  is  challenging  both  in  terms  of  diagnosis
and  treatment.  It  requires  a  rigorous  approach  that  must
take  a  number  of  factors  into  consideration,  and  of  these,
chest  imaging  occupies  a  central  place.  The  chest  CT
scan  is  clearly  established  as  superior  to  the  standard
chest  radiograph  in  this  context.  On  CT,  the  presence  of
lesions  that  are  not  visible  on  radiography  can  be  con-
ﬁrmed  and  its  use  assists  in  guiding  the  diagnosis  of  aetiology
when  considered  together  with  the  rest  of  the  patient
data.
Indications for chest CT
There  are  three  main  situations  in  which  chest  computed
tomography  is  indicated:
• when  haematological  disease  is  diagnosed.  This  is  espe-
cially  so  in  the  case  of  lymphoma;
• if there  is  a  suspicious  chest  sign  at  any  time  during  the
patient’s  management;
• if the  patient  presents  unexplained  fever,  especially  if
they  have  neutropenia  or  are  receiving  haematopoietic
stem  cells.
Chest  CT  is  also  useful  for  conﬁrming  the  nature
of  any  opacities  that  may  have  been  demon-
strated  on  chest  radiography.  Finally,  it  is  crucial
for  guiding  bronchoscopy  for  taking  targeted  sam-
ples  (bronchoalveolar  lavage,  transbronchial  needle
aspiration).
Key factors for interpreting an
abnormality detected on chest CT
The  management  of  these  patients  is  complex  due  to  the
wide  range  of  possible  aetiologies  that  must  be  considered
when  a  lung  inﬁltrate  is  found.  Because  they  are  common
and  serious,  infections  must  be  the  ﬁrst  cause  to  be  con-
sidered  as  a  matter  of  routine.  However,  at  least  a  quarter
of  lung  inﬁltrates  presented  by  patients  with  haematologi-
cal  malignancies  have  a  non-infectious  cause  (drug  toxicity,
heart  failure,  speciﬁc  lung  involvement  connected  to  the
underlying  disease,  intra-alveolar  haemorrhage,  etc.)  [2].  It
is  nonetheless  important  to  note  that  these  non-infectious
causes  of  lung  disorders  can  coexist  with  an  infectious  aeti-
ology.
In  the  same  way,  among  the  infectious  causes  there
are  numerous  pathogens  (bacteria,  viruses,  fungi,  para-
sites)  that  can  cause  pneumonia  and  co-infections  are
common  when  these  predisposing  factors  are  present,  mak-
ing  the  interpretation  of  radiological  abnormalities  even
more  complex.  This  means  that  in  this  context  there
are  a  number  of  factors  that  need  to  be  considered  in
order  to  interpret  pulmonary  abnormalities  seen  on  radi-
ology.
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actors connected to haematological disease
ype  of  haematological  disease
ot  every  type  of  haematological  malignancy  is  found
ith  every  cause  of  lung  disease.  For  example,  while
peciﬁc  involvement  of  the  pulmonary  parenchyma  is  com-
on  in  lymphoma,  it  is  very  rare  in  myeloma  or  chronic
yeloid  leukaemia.  Similarly,  certain  groups  of  haema-
ological  malignancy  are  often  associated  with  a similar
reatment  proﬁle.  This  means  that  the  kind  of  immuno-
uppression  seen  is  often  similar  and  the  risks  of  infection
re  comparable.  This  is  the  case,  for  example,  with  the
idespread  use  of  rituximab  to  treat  lymphoid  diseases,
hich  are  associated  with  an  increased  incidence  of  pneu-
ococcal  or  haemophilus  inﬂuenzae  respiratory  infections.
nother  example  is  the  administration  of  ﬂudarabine  to
reat  chronic  lymphocytic  leukaemia,  which  leads  to  an
ncreased  risk  of  pneumocystosis.  Furthermore,  numerous
reatments  that  are  often  prescribed  for  speciﬁc  haema-
ological  diseases  have  a  well-established  association  with
otential  lung  toxicity  (www.pneumotox.com): some  exam-
les  are  bleomycin  in  Hodgkin’s  lymphoma,  cytarabine,  used
o  treat  acute  leukaemias,  and  tyrosine  kinase  inhibitors  in
hronic  myeloid  leukaemia  [3].
In  addition,  there  are  various  non-infectious  lung  dis-
rders  that  often  complicate  the  course  of  speciﬁc
aematological  malignancies:  some  examples  are  sarcoid-
ike  granulomatosis  in  Hodgkin’s  lymphoma,  organising
neumonia  or  eospinophilic  pneumonia  in  myelodysplastic
yndromes,  and  amyloidosis  in  myeloma  [4,5].
Finally,  interpreting  a  chest  CT  scan  is  complicated  by
he  fact  that  the  same  type  of  pulmonary  infection  can
resent  differently  depending  on  the  underlying  disease.
his  is  the  case  in  invasive  pulmonary  aspergillosis,  which
lmost  always  presents  as  a  nodule  with  a  peripheral  halo
n  patients  on  induction  or  consolidation  treatment  for  an
cute  leukaemia,  while  it  may  have  a  more  varied  presenta-
ion  in  patients  being  treated  for  a  lymphoid  haematological
isease  or  who  have  received  an  allogeneic  HSC  transplant
6].
tage of the haematological
isease/Treatment phase
t  is  essential  to  be  aware  of  the  stage  of  the  patient’s
aematological  disease  as  well  as  their  current  treatment
hase  in  order  to  be  able  to  interpret  pulmonary  radiological
maging.  If  pulmonary  opacities  are  identiﬁed  in  well-
ontrolled  haematological  disease  this  means  that  a  speciﬁc
nvolvement  caused  by  the  underlying  disease  is  unlikely.
he  presence  of  ground  glass  opacities  together  with  sep-
al  thickening  on  a  chest  CT  scan  carried  out  in  a  patient
resenting  oxygen  desaturation  a  few  hours  after  hyperhy-
ration  in  induction  chemotherapy  for  an  acute  leukaemia  or
onditioning  for  an  allogeneic  HSC  transplant  means  that  the
nitial  hypothesis  that  suggests  itself  is  pulmonary  oedema;
ntra-alveolar  haemorrhage  must  be  considered  in  a  patient
ith  signiﬁcant  thrombocytopenia,etc.
Allogeneic  HSC  transplant  is  a  treatment  phase  that  may
ell  be  complicated  by  a  variety  of  infectious  and  non-
nfectious  lung  disorders  [7].  Apart  from  the  infectious  lung
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iseases  that  are  very  common  both  during  the  period  of
plasia  and  during  follow-up  of  patients  receiving  immuno-
uppressant  treatment  for  graft  versus  host  disease,  these
atients  can  also  develop  bronchiolitis  obliterans,  an  organ-
sing  pneumonia  or  a  diffuse  interstitial  lung  disease  [7].
roﬁle of immunodeﬁciency
he  patient’s  proﬁle  of  immunodeﬁciency  deﬁnes  the  type  of
nfectious  risks  that  they  are  exposed  to.  It  is  related  to  the
nderlying  haematological  disease  and  the  immunosuppress-
nt  treatments  received,  and  it  depends  on  the  predicted
uration  and  extent  of  immunosuppression:
aranulocytosis  and/or  granulocyte  disorders,  often
present  during  chemotherapy;
atibody-mediated  immunity  deﬁciency,  which  is
expressed  as  hypogammaglobulinemia  and  is  often
found  in  chronic  lymphocytic  leukaemias,  myelomas,  HSC
transplants,  and  treatment  with  anti-CD20  antibodies;
cell-mediated  immunity  deﬁciency,  which  is  associated
with  long-term  corticosteroid  use,  treatment  with  anti-
CD52  antibodies  or  purine  analogues,  HSC  transplants,  and
lymphoproliferative  disorders;
spleen  dysfunction  secondary  to  a  splenectomy,  or  splenic
or  total  body  irradiation.
These  different  immunosuppression  proﬁles  often  arise
n  the  same  patient  at  different  stages  in  the  management
f  their  haematological  malignancy  and  this  complicates  the
ssessment  of  each  patient.
Each  immunosuppression  proﬁle  is  connected  with  a
articular  vulnerability  to  one  pathogen  or  another.  For
xample,  pneumococcal  or  Haemophilus  inﬂuenzae  pneu-
onias  are  especially  common  in  patients  who  have
n  antibody-mediated  immunity  deﬁciency;  lung  diseases
aused  by  bacteria  may  be  the  most  common  type  found  in
atients  with  neutropenia,  but  an  invasive  fungal  infection
ill  be  routinely  considered  in  prolonged  neutropenia,  and
neumocystosis  or  community-acquired  viral  lung  diseases
re  common  in  patients  with  a  deﬁciency  in  cell-mediated
mmunity.
reatments for infection received
f  a  patient  presents  a  fever  or  a  suspicious  pulmonary  sign,
hose  on  treatment  for  a  haematological  malignancy  will
rgently  receive  a  broad-spectrum  empirical  treatment  for
nfection  in  view  of  their  immunodeﬁciency,  often  before  a
hest  CT  scan  has  been  carried  out.  In  parallel,  there  are  a
umber  of  prophylactic  or  pre-emptive  treatments  they  may
eceive.  These  treatments  must  be  taken  into  account  when
bnormalities  seen  on  the  CT  scan  are  being  interpreted.
Empirical  treatment  is  largely  applicable  during  periods
f  febrile  neutropenia  and  consists  of  broad-spectrum
ntibiotics  effective  against  Gram-negative  bacilli  (includ-
ng  Pseudomonas, often  responsible  for  lung  disorders  in
hese  circumstances)  and  Gram-positive  cocci.  If  fever  per-
ists  beyond,  72  hours  an  anti-fungal  treatment  will  be
dded.
Prophylactic  treatment  consists  of  administering  anti-
nfective  agents  to  a  whole  population  of  patients  in  order
o  reduce  the  risk  of  infection  in  this  population.  The  most
n
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ffective  prophylaxis  is  trimethoprim/sulfamethoxazole,
hich  makes  a  diagnosis  of  pneumocystosis  very  unlikely.  If
 patient  presents  spleen  dysfunction,  this  justiﬁes  the  use
f  anti-pneumococcal  prophylaxis  in  order  to  limit  the  risk
f  pneumococcal  lung  disorders.  Patients  with  aplasia  after
hemotherapy  for  leukaemia  or  who  have  been  treated  for
raft  versus  host  disease  after  an  allogeneic  HSC  transplant
an  be  given  anti-fungal  prophylaxis  that  is  effective  against
spergillus.
Pre-emptive  therapy  involves  routinely  and  repeatedly
sing  microbiology  screening  techniques  in  order  to  treat
 patient  at  risk  before  they  develop  clinical  symptoms.
ne  example  of  this  is  the  practice  of  routinely  perform-
ng  peripheral  blood  PCR  to  screen  for  CMV  in  allogeneic
SC  transplant  recipients,  with  antiviral  treatment  start-
ng  as  soon  as  there  is  an  increased  viral  load.  This  has
ed  to  a  considerable  reduction  in  the  incidence  of  CMV
neumonia  in  this  population.  Indeed,  during  the  1980s  the
ncidence  of  CMV  pneumonia  in  allogeneic  HSC  transplant
ecipients  was  greater  than  30%,  and  today  it  is  estimated  at
%  [8,9].
Nonetheless,  clinicians  must  remain  vigilant,  espe-
ially  after  these  preventive  treatments  have  been
topped  because  immunosuppression  can  persist  or
eappear.
atient history
he  background  against  which  radiological  abnormalities
ave  been  found,  as  well  as  the  way  in  which  any  respi-
atory  symptoms  have  set  in,  needs  to  be  incorporated
nto  the  interpretation  that  is  made  of  the  chest  CT  scan.
he  ﬁnding  of  centrilobular  micronodules  in  a  patient  who
as  developed  a  debilitating  dry  cough  and  fever  a  few
ays  after  exposure  to  a  contagion  during  an  epidemic
f  community-acquired  respiratory  virus,  makes  the  diag-
osis  of  community-acquired  viral  pneumonia  very  likely.
n  the  same  way,  the  geographic  origin  of  a  patient  or
ny  previous  exposure  to  tuberculosis  becomes  impor-
ant  when  interpreting  the  ﬁnding  of  necrotic  mediastinal
ymphadenopathy,  irrespective  of  what  the  underlying
aematological  disease  is.  It  is  signiﬁcant  if  the  patient
ses  tobacco  when  a  pulmonary  nodule  is  found,  espe-
ially  in  a  haematological  disease  that  is  associated  with
n  increased  risk  of  cancers,  such  as  chronic  lymphocytic
eukaemia.
linical signs
part  from  fever,  which  is  suggestive  of  an  infectious  cause
f  lung  disease,  respiratory  clinical  signs  add  very  little  in
erms  of  pointing  towards  a  speciﬁc  aetiology.  This  means
hat,  for  example,  even  though  chest  pain  and  haemoptysis
re  often  associated  with  invasive  pulmonary  aspergillo-
is,  these  symptoms  are  often  absent  and  they  can  be
ound  in  other  situations,  so  they  are  not  speciﬁc.  It  is
are  to  see  signs  elsewhere  in  the  body,  but  these  can  be
xtremely  useful  for  diagnosis.  For  example,  the  combi-
ation  of  cerebral  involvement  and  a  lung  inﬁltrate  will
oint  to  a  mycobacterial  infection,  toxoplasmosis,  fungal
nfection,  or  nocardiosis.  Cutaneous  involvement  may  be
uggestive  of  mycosis  (candidiasis,  fusariosis,  aspergillosis)
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or  nocardiosis.  Sinus  involvement  may  point  to  mycosis
(aspergillosis,  mucormycosis).
Analysing CT scan abnormalities
The  chest  CT  scan  has  become  the  key  investigation  for
diagnosing  lung  disease  in  haematology  patients.  The  cur-
rent  question  is  one  of  determining  how  useful  CT  is  in
terms  of  pinpointing  the  aetiology  of  lung  involvement  in  this
context.  There  are  several  approaches  that  can  contribute
answers  to  this  problem:
• the  description  of  the  most  decisive  CT  scan  abnormali-
ties  that  are  present  in  small  groups  of  patients  with  an
identiﬁed  lung  disorder;  this  applies  for  example  to  the
centrilobular  micronodules  that  are  almost  always  found
in  patients  with  a  lung  disease  caused  by  the  Parainﬂuen-
zae  virus  [10]  or  the  nodule  with  a  halo  sign  in  neutropenic
leukaemia  patients  [11];
• studies  into  the  correlation  between  CT  features  and
pulmonary  histology  ﬁndings  that  allow,  for  example,
a  description  to  be  made  of  the  unique  CT  features
of  organising  pneumonia  in  patients  who  have  under-
gone  allogeneic  HSC  transplant  [12]  or  those  of  invasive
pulmonary  aspergillosis  in  view  of  the  underlying  pre-
disposing  factors  [13—15]. These  studies  promote  both
an  anatomical  and  pathophysiological  reading  of  the  CT
scan,  which  is  very  helpful  in  these  complex  patients.
Taken  as  such,  centrilobular  micronodules  are  sugges-
tive  of  a  pathology  targeting  bronchiolar  tissue  such  as
community-acquired  viral  infections,  invasive  aspergillo-
sis  in  allogeneic  HSC  transplant  recipients,  or  bronchiolitis
caused  by  Haemophilus. In  the  same  way,  septal  thicken-
ing,  for  example,  points  to  a  pathology  of  the  lymphatic
system:  lymphangitis,  pulmonary  oedema,  etc.;
• other  studies  have  attempted  to  associate  speciﬁc  CT  scan
features  with  a  given  pathogen.  For  example,  it  has  been
suggested  that  bacterial  pneumonia  is  usually  demon-
strated  as  alveolar  consolidation,  that  fungal  lung  disease
presents  as  nodules  in  90%  of  cases,  nearly  half  of  which
are  thought  to  be  cavitated,  and  that  pneumocystosis  is
associated  with  ground  glass  opacities  in  100%  of  cases
[16].
However,  there  is  no  CT  scan  feature  that  is  pathog-
nomonic  for  a  particular  pathogen  and  CT  alone  is  therefore
not  enough  to  make  a  microbiological  or  histological  diag-
nosis.  This  is  even  more  the  case  in  view  of  recent  data
suggesting  that  CT  features  of  a  given  infectious  pneumonia
differ  depending  on  the  patient’s  underlying  predisposing
factors.  For  example,  while  the  halo  sign  is  almost  always
seen  in  invasive  pulmonary  aspergillosis  in  patients  with  neu-
tropenia  being  treated  for  acute  leukaemia,  it  is  less  often
present  in  the  wider  population  of  haematology  patients
[17].  Moreover,  whether  the  halo  sign  or  cavitated  nodules
in  aspergillosis  are  found  depends  on  how  early  the  diag-
nosis  is  being  made.  While  the  halo  sign  appears  early  and
transiently,  cavitation  develops  later  [11]. Finally,  although
the  nodule  with  a  halo  may  be  strongly  associated  with  the
diagnosis  of  invasive  aspergillosis,  it  can  also  be  one  charac-
teristic  of  other  less  common  and  emerging  invasive  fungal
lung  diseases  [18].219
icrobiology and histology tools
he  CT  scan  is  carried  out  at  an  increasingly  early  stage  for
he  investigation  of  lung  disease  in  haematology  patients
nd  it  is  almost  always  done  before  a  bronchoscopy  and  of
ourse  before  a  lung  biopsy.  Apart  from  when  the  chest  CT
can  is  indicated  to  investigate  a  positive  Aspergillus  anti-
en  test  as  part  of  routine  monitoring,  microbiology  and
istology  results  are  not  usually  available  before  the  CT
can  has  been  carried  out  and  this  means  that  they  must
e  considered  later  in  the  interpretation  of  the  radiological
ndings  in  a  given  patient.  Nonetheless,  in  addition  to  their
alue  for  individual  patients,  they  are  very  useful  in  further-
ng  our  understanding  of  opacities  found  on  CT  scans.  For
xample,  progress  that  has  been  made  in  molecular  biology
as  meant  that  numerous  community-acquired  respiratory
iruses  causing  lung  disease  in  haematology  patients  can
e  identiﬁed  and  their  incidence  determined  (metapneu-
ovirus,  parainﬂuenzae  virus,  etc.)  [10,19].
onclusion
he  chest  CT  scan  has  undeniably  become  a  crucial  aspect
n  the  diagnosis  of  lung  disease  in  patients  being  man-
ged  for  haematological  malignancies.  Although  it  may
ot  be  possible  to  make  a  deﬁnitive  diagnosis  of  aetiol-
gy  based  solely  on  analysing  CT  scan  ﬁndings  in  these
omplex  patients,  there  are  some  abnormalities  that  are
ighly  suggestive  for  particular  diagnoses.  CT  must  there-
ore  allow  the  clinician  to  put  forward  and  prioritise  possible
iagnoses  that  may  then  be  considered  in  view  of  clinical
nformation  and  laboratory  study  results.  There  must  be
ultidisciplinary  involvement  in  the  management  of  these
ung  disease  patients  and  there  must  be  an  ongoing  dialogue
etween  the  radiologist  and  the  clinician  as  soon  as  any  new
ata  is  discovered.
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